CYTOMEGALOVIRUS INFECTION AS A CAUSE OF THERAPY REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA IN A PATIENT WITH STEROID INDUCED IMMUNOSUPPRESSION (SIE 2026) - Oct 6, 2026 - Abstract #SP016; "Caplacizumab was added...A septic trigger of unknown origin was hypothe- sized, and empirical antibiotic therapy was initiated.After ap- proximately three weeks without significant improvement, Rituximab was introduced, resulting in clinical and laborato- ry improvement within seven days, including rising hemo- globin and platelet counts and improved renal function.How- ever, after a few days, laboratory tests demonstrated dis- ease relapse despite ongoing combined therapy...Virolog- ical testing revealed significant CMV viremia.Antiviral thera- py with Ganciclovir was initiated alongside TTP specific treatment...Early identification of CMV infection is therefore crucial in patients with TTP, particularly in cases of therapeutic resis- tance or unexplained relapse. Further studies are needed to clarify whether effective preventive strategies against CMV should be implemented in patients with pharmacologically induced immunosuppression."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Hepatology • Infectious Disease • Thrombocytopenic Purpura
|